NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced today a collaboration to improve early diagnosis and treatment of neurodegenerative diseases. The NeuroSense-QuantalX collaboration comes following NeuroSense’s recent report on new biomarker data in Alzheimer’s disease (AD) and its plans to initiate a Phase 2 AD clinical trial in the first half of 2023.